Identifying Failure Predictors in Thyroid Nodule Radiofrequency Ablation Using Multivariate Analysis: A Single‐Centre Experience
Clinical Endocrinology · 2026
DOI: 10.1111/cen.70125 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Endocrinology, 2026. Verfasst von Shmuel Wechsler und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Shamir Medical Centre, Be'er Ya'akov, Israel. Hauptthemen laut MEDLINE: Thyroid Nodule, Radiofrequency Ablation. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Radiofrequency ablation (RFA) has become an established minimally invasive treatment for benign thyroid nodules (BTN), offering excellent safety and efficacy. However, factors predicting treatment success and post‐procedural thyroid dysfunction remain incompletely understood. This study aimed to perform a preliminary evaluation of clinical, procedural, and biochemical predictors of RFA outcomes in a real‐world consecutive patient cohort. Study Design and Methods A retrospective analysis was conducted on consecutive patients who underwent ultrasound‐guided RFA for cytologically benign thyroid nodules between January 2018 and March 2024 at a single tertiary medical centre. Demographic, sonographic, procedural, and biochemical variables, including thyroid‐stimulating hormone (TSH), thyroglobulin (Tg), and anti‐Tg antibodies, were analysed. The primary endpoint was the Volume Reduction Ratio (VRR), with ≥ 50% defined as procedural success.
Results
Sixty‐two patients (mean age 52.6 years; 85.5% female) were included. The median best VRR achieved was 61.9% (IQR 46.6–74.5), with 71% of patients attaining ≥ 50% reduction. Higher pre‐treatment Tg levels were significantly associated with reduced VRR ( p < 0.001) and remained independently associated with procedural failure in an exploratory multivariable model (OR 0.87 per 10 ng/mL increase, p = 0.011). Pretreatment TSH levels showed a univariate positive trend but did not reach statistical significance on multivariate analysis. Two patients (3.2%) developed hypothyroidism post‐RFA, both with positive anti‐Tg antibodies (total 13 patients had positive anti Tg Ab). The overall complication rate was 6.5%, with no major adverse events.
Conclusions
Our results suggest that pre‐treatment thyroglobulin levels may serve as a potential biochemical predictor of RFA success in benign thyroid nodules, while antibody positivity may suggest susceptibility to post‐ablation hypothyroidism. While most existing literature focuses on imaging features (e.g., sonographic features) or surgeon technique, our findings highlight the unique importance of biochemical characteristics. Incorporating biochemical profiling into pre‐procedural assessment could refine patient selection and enhance individualised treatment planning. Future prospective studies are warranted to validate Tg as a biomarker of RFA response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, Shamir Medical Centre, Be'er Ya'akov, Israel.
- Gray Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel.
ORCID-Profile: Shmuel Wechsler, Jacob Pitaro
Zitieren
APA
Wechsler, S., Shcherbaeva, T., Pitaro, J., & Kalmovich, L. M. (2026). Identifying Failure Predictors in Thyroid Nodule Radiofrequency Ablation Using Multivariate Analysis: A Single‐Centre Experience. Clinical Endocrinology. https://doi.org/10.1111/cen.70125
Vancouver
Wechsler S, Shcherbaeva T, Pitaro J, Kalmovich LM. Identifying Failure Predictors in Thyroid Nodule Radiofrequency Ablation Using Multivariate Analysis: A Single‐Centre Experience. Clinical Endocrinology. 2026. doi:10.1111/cen.70125
BibTeX
@article{Wechsler2026,
author = {Wechsler, Shmuel and Shcherbaeva, Tanya and Pitaro, Jacob and Kalmovich, Limor Muallem},
title = {Identifying Failure Predictors in Thyroid Nodule Radiofrequency Ablation Using Multivariate Analysis: A Single‐Centre Experience},
journal = {Clinical Endocrinology},
year = {2026},
doi = {10.1111/cen.70125}
}
EUVIMED